These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21877764)

  • 1. Pirlindole in the treatment of depression and fibromyalgia syndrome.
    Branco JC; Tomé AM; Cruz MR; Filipe A
    Clin Drug Investig; 2011 Oct; 31(10):675-89. PubMed ID: 21877764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind randomized placebo-controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor, in the treatment of depression.
    De Wilde JE; Geerts S; Van Dorpe J; Bruhwyler J; Géczy J
    Acta Psychiatr Scand; 1996 Dec; 94(6):404-10. PubMed ID: 9020990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression.
    Tanghe A; Geerts S; Van Dorpe J; Brichard B; Bruhwyler J; Géczy J
    Acta Psychiatr Scand; 1997 Aug; 96(2):134-41. PubMed ID: 9272198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pirlindole in the treatment of depression: a meta-analysis.
    Macedo A; Leiria E; Filipe A
    Clin Drug Investig; 2011; 31(1):61-71. PubMed ID: 21053988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the antidepressant pirlindole and its dehydro-derivative on the activity of monoamine oxidase-A and on GABAA receptors.
    Medvedev AE; Shvedov VI; Chulkova TM; Fedotova OA; Saederup E; Squires RF
    Neurochem Res; 1996 Dec; 21(12):1521-6. PubMed ID: 8953568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pirlindole: a selective reversible inhibitor of monoamine oxidase A. A review of its preclinical properties.
    Bruhwyler J; Liégeois JF; Géczy J
    Pharmacol Res; 1997 Jul; 36(1):23-33. PubMed ID: 9368911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of the antidepressant pirlindole and its dehydro-derivative on the activity of monoamine oxidase A and GABAA receptor binding.
    Medvedev AE; Shvedov VI; Chulkova TM; Fedotova OA; Saederup E; Squires RF
    J Neural Transm Suppl; 1998; 52():337-42. PubMed ID: 9564636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of pirlindole, a selective RIMA, and its two enantiomers using biochemical and behavioural techniques.
    Bruhwyler J; Liégeois JF; Gérardy J; Damas J; Chleide E; Lejeune C; Decamp E; de Tullio P; Delarge J; Dresse A; Géczy J
    Behav Pharmacol; 1998 Dec; 9(8):731-7. PubMed ID: 9890262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome.
    Tort S; Urrútia G; Nishishinya MB; Walitt B
    Cochrane Database Syst Rev; 2012 Apr; (4):CD009807. PubMed ID: 22513976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on pharmacotherapy for the treatment of fibromyalgia.
    Calandre EP; Rico-Villademoros F; Slim M
    Expert Opin Pharmacother; 2015 Jun; 16(9):1347-68. PubMed ID: 26001183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological properties of 2,3,3a,4,5,6-hexahydro-8-methyl-1H-pyrazino [3,2,1-j,k]carbazol hydrochloride (pirlindole), a new antidepressant.
    Mashkovsky MD; Andrejeva NI
    Arzneimittelforschung; 1981; 31(1):75-9. PubMed ID: 7194096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of chronic stress on hippocampal adult neurogenesis and dendritic plasticity are reversed by selective MAO-A inhibition.
    Morais M; Santos PA; Mateus-Pinheiro A; Patrício P; Pinto L; Sousa N; Pedroso P; Almeida S; Filipe A; Bessa JM
    J Psychopharmacol; 2014 Dec; 28(12):1178-83. PubMed ID: 25315831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of monoamine oxidase by pirlindole analogues: 3D-QSAR and CoMFA analysis.
    Medvedev AE; Veselovsky AV; Shvedov VI; Tikhonova OV; Moskvitina TA; Fedotova OA; Axenova LN; Kamyshanskaya NS; Kirkel AZ; Ivanov AS
    J Chem Inf Comput Sci; 1998; 38(6):1137-44. PubMed ID: 9845968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB; Weinstock M
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Inhibition of monoamine oxidase A and B in the heart and brain of the rat with amitriptyline, pargyline and pirlindol].
    Schraven E; Reibert R
    Arzneimittelforschung; 1984; 34(10):1258-60. PubMed ID: 6542783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoamine oxidase A inhibitory potency and flavin perturbation are influenced by different aspects of pirlindole inhibitor structure.
    Hynson RM; Wouters J; Ramsay RR
    Biochem Pharmacol; 2003 Jun; 65(11):1867-74. PubMed ID: 12781338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal selegiline.
    Patkar AA; Pae CU; Zarzar M
    Drugs Today (Barc); 2007 Jun; 43(6):361-77. PubMed ID: 17612708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoamine oxidase inhibitors: a new generation.
    Robinson DS
    Psychopharmacol Bull; 2002; 36(3):124-38. PubMed ID: 12473970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibition of brain monoamine oxidase in the rat by multiple pyrazidol administration].
    Verevkina IV; Asnina VV; Gorkin VZ; Mashkovskiĭ MD
    Biull Eksp Biol Med; 1985 May; 99(5):583-4. PubMed ID: 4005414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The new antidepressant tetrindole].
    Mashkovskiĭ MD; Glushkov RG; Shvedov VI; Andreeva NI; Golovina SM
    Eksp Klin Farmakol; 1993; 56(2):3-6. PubMed ID: 8348033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.